2026 / 09 / 08
JW Therapeutics Announces NMPA Approval to Extend Cryopreservation Period of Sorted T Cells for Carteyva® to 36 Months, Further Enhancing CAR-T Manufacturing and Clinical Value
Learn more
2026 / 06 / 09
EULAR 2026 | JW Therapeutics Presents Two Positive Study Results of Relma-cel for SLE and SSc at the European Congress of Rheumatology
Learn more
2026 / 05 / 09
ASGCT 2026 | JW Therapeutics Presents Preclinical Data of JWCAR201 and JWCAR239 at the 29th Annual Meeting of the American Society of Gene & Cell Therapy
Learn more
2026 / 03 / 05
JW Therapeutics' Relma-cel IIT Study in Systemic Sclerosis (SSc) Selected as Late-Breaking Abstract at the Systemic Sclerosis World Congress (SSWC)
Learn more
2025 / 12 / 08
JW Therapeutics Presents JWCAR201 IIT Study Data at the 67th American Society of Hematology Annual Meeting
Learn more
2025 / 12 / 07
JW Therapeutics' Carteyva® Successfully Included in the First Edition of the National Healthcare Security Administration's Commercial Health Insurance Innovative Drug Directory
Learn more
2025 / 10 / 30
JW Therapeutics and Regeneron Expand Strategic Collaboration Agreement to Advance TCR-T Cell Therapy Development
Learn more
2025 / 10 / 21
JW Therapeutics Submitted data from the Phase I study of Relma-cel in Chinese adult patients with active systemic lupus erythematosus to China National Medical Products Administration
Learn more
2025 / 10 / 09
National Medical Products Administration has officially accepted the post-marketing supplemental application for Carteyva®, which uses an in-house produced lentiviral vector
Learn more
2025 / 09 / 26
JW Therapeutics Completes First Patient Infusion in Clinical Study of JWCAR239 for Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Learn more
2025 / 06 / 04
JW Therapeutics Announces Approval of Carteyva® (Relmacabtagene Autoleucel Injection) for Marketing in Macao
Learn more
2025 / 05 / 28
NMPA ACCEPTANCE OF THE SUPPLEMENTAL BIOLOGICAL LICENSE APPLICATION FOR CARTEYVA® AS SECOND-LINE TREATMENT IN RELAPSED OR REFRACTORY LARGE B-CELL LYMPHOMA INELIGIBLE FOR AUTOLOGOUS STEM CELL TRANSPLANTATION
Learn more
2025 / 04 / 29
Next Generation MAGE-A4 TCR-T cell program in China
Learn more
2025 / 04 / 23
JW Therapeutics Announces sLVV License Agreement with Juno Therapeutics
Learn more
2025 / 01 / 10
Receipt of Breakthrough Therapy Designation for Carteyva® in China as Second-line Treatment in Relapsed or Refractory adult Large B-cell Lymphoma
Learn more